Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders

In pediatric patients, the selective serotonin reuptake inhibitors (SSRIs) escitalopram and citalopram (es/citalopram) are commonly prescribed for anxiety and depressive disorders. However, pharmacogenetic studies examining CYP2C19 metabolizer status and es/citalopram treatment outcomes have largely...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Stacey L. Aldrich, Ethan A. Poweleit, Cynthia A. Prows, Lisa J. Martin, Jeffrey R. Strawn, Laura B. Ramsey
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2019-02-01
Schriftenreihe:	Frontiers in Pharmacology
Schlagworte:	pharmacogenetics CYP2C19 SSRI (selective serotonin reuptake inhibitor) antidepressant anxiety disorders depressive disorder
Online-Zugang:	https://www.frontiersin.org/article/10.3389/fphar.2019.00099/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!